Can anticancer therapy be improved by sequential use of cytotoxic and cytostatic (differentiating or immunomodulating) agents to suppress tumor cell phenotypic diversification?
Lotan
R
R
Department of Tumor Biology, University of Texas-M.D. Anderson Hospital and Tumor Institute, Houston 77030.
Nicolson
G L
GL
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D010641:Phenotype
D000970:Antineoplastic Agents